Protagonist Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
ICOTYDE, the first oral IL-23 receptor blocker, received FDA approval for moderate-to-severe plaque psoriasis, supported by robust phase III data and a clean safety profile. The approval triggers significant milestone payments and positions the product to compete with and expand beyond injectable biologics.
-
The discussion highlighted a robust pipeline of novel oral and injectable peptide therapeutics, with two lead assets nearing potential approval and a diversified R&D focus in immunology, hematology, and obesity. Strategic partnerships and financial strength support continued innovation and market expansion.
-
The company leverages deep expertise in peptide therapeutics, with two late-stage partnered assets expected to receive regulatory decisions in Q3. Strong partnerships, a robust pipeline in I&I and obesity, and a solid financial position enable continued innovation and multiple value inflection points in 2026.
-
Two partnered products are expected to receive FDA approval in 2026, with significant milestone payments and surplus cash anticipated. The pipeline features first-in-class oral IL-23 and IL-17 assets, innovative obesity candidates, and a robust peptide platform, positioning for market disruption and shareholder value creation.
-
The session highlighted a robust pipeline with two near-term launches, strong clinical data for oral IL-23 in psoriasis and IBD, and significant market opportunities. Strategic partnerships, financial independence, and a focus on innovation and differentiation underpin future growth.
-
Significant growth is expected over the next two years with two near-term product launches, a robust pipeline of fully owned and partnered assets, and strong financials supporting both R&D and shareholder returns. Strategic focus includes expanding discovery, pharma partnerships for large markets, and operational scaling.
Fiscal Year 2025
-
Breakthrough designation was regained for rusfertide after strong phase 3 results in polycythemia vera, with NDA filing planned by year-end and a $1–2 billion market opportunity. Strategic opt-in/opt-out decisions could fund R&D and share buybacks. Pipeline assets show strong differentiation and clinical progress.
-
The summit highlighted advances in peptide therapeutics, with rusfertide progressing toward NDA filing and a strategic partnership with Takeda. Icotrokinra's strong clinical profile and J&J partnership position it for significant market impact, while new obesity and IL-17 programs expand the pipeline.
-
PN-477, a novel oral and injectable triple agonist for obesity, was nominated as a development candidate, showing strong preclinical efficacy, favorable pharmacokinetics, and potential for best-in-class status. Both formulations will advance in parallel, supported by a robust cash position and strategic flexibility.
-
ASCO plenary data showed a new PV drug with strong efficacy, symptom improvement, and safety, earning "practice-changing" recognition and support for standard of care adoption. Strategic partnerships with Takeda and J&J drive late-stage and early pipeline progress, while robust financial prospects prompt a focus on capital allocation.
-
VERIFY phase III results show rusfertide significantly improves hematocrit control, reduces phlebotomy needs, and enhances quality of life in PV patients, with a favorable safety profile. Regulatory filing is planned for Q4 2025, and commercial prospects are strong.
-
Rusfertide achieved robust efficacy and safety in the phase III VERIFY study for polycythemia vera, meeting all primary and secondary endpoints and showing significant improvements in clinical response and patient-reported outcomes. Regulatory filings are planned with strong commercial potential and continued collaboration with Takeda.
-
Rusfertide demonstrated rapid and sustained hematocrit control, reduced phlebotomy need, and improved symptoms in phase II PV studies, with a favorable safety profile. The ongoing phase III VERIFY trial is expected to confirm these benefits and support broad adoption, targeting a significant unmet need in PV.
-
The session highlighted robust progress in peptide therapeutics, with late-stage assets rusfertide and icotrokinra targeting NDA filings by year-end and significant market potential. Discovery programs in IL-17, obesity, and oral hepcidin are advancing, supported by strong partnerships and a cash runway through 2028.
Fiscal Year 2024
-
Icotrokinra, an oral IL-23 blocker, achieved strong phase III results and is set to launch as the leading oral psoriasis therapy, with a robust royalty structure and high patient satisfaction. The pipeline includes a potent oral IL-17 candidate and an obesity program, both advancing toward clinical milestones.
-
PN-881, a fully owned oral IL-17 antagonist, was nominated as a development candidate, showing best-in-class potency and strong preclinical results. With a robust cash runway, the company plans to advance PN-881 into clinical trials and expand its pipeline, while maintaining strategic flexibility.
-
Multiple phase III studies for oral peptide therapeutics in psoriasis, ulcerative colitis, and polycythemia vera are progressing, with key data expected by year-end and early next year. Strategic partnerships with J&J and Takeda offer significant milestone and royalty opportunities, while the pipeline expands into IL-17 and obesity indications.
-
Two late-stage assets, JNJ-2113 and rusfertide, are advancing rapidly, with key data readouts expected by year-end and early next year. Strong partnerships, a robust cash position, and a growing early pipeline support ongoing innovation and potential commercialization.